pharmaceutical investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
pharmaceutical investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
pharmaceutical investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
pharmaceutical investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
pharmaceutical investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
pharmaceutical investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
pharmaceutical investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
cannabis investing Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs
cannabis investing Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
life science investing Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
